thalidomide has been researched along with HIV Coinfection in 127 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate safety and efficacy of thalidomide in the treatment of prurigo nodularis in a group of human immunodeficiency virus (HIV)-infected patients whose condition was recalcitrant to standard treatment." | 9.11 | Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. ( Berger, T; Maurer, T; Poncelet, A, 2004) |
| "A multicenter, double-blind, randomized, placebo-controlled clinical trial was conducted to determine the safety and efficacy of thalidomide for treating esophageal aphthous ulceration in persons infected with human immunodeficiency virus (HIV)." | 9.09 | Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group. ( Basgoz, N; Chernoff, M; Fahey, JL; Fox, L; Hooton, TM; Jackson, JB; Jacobson, JM; MacPhail, LA; Sha, BE; Shikuma, CM; Simpson, DM; Spritzler, J; Trapnell, CB; Wohl, DA; Wu, AW, 1999) |
| "An interim analysis of data from a NIAID-supported study determined that thalidomide effectively and safely heals severe mouth ulcers in persons with HIV infection." | 9.08 | Thalidomide effective treatment for AIDS-related mouth ulcers. ( Randall, P, 1995) |
| "A phase II trial is beginning using thalidomide as a treatment for chronic diarrhea in HIV-infected patients." | 9.08 | Thalidomide for diarrhea. ( , 1996) |
| "Celgene Corporation initiated a phase II safety and efficacy trial for Synovir (thalidomide) in the treatment of chronic intractable diarrhea in HIV-positive patients." | 9.08 | Thalidomide used to treat chronic diarrhea in HIV-positive patients. ( , 1996) |
| "Thalidomide appears to be highly effective for oropharyngeal apthous ulcers in HIV-infected patients." | 9.08 | A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers. ( Alexander, LN; Wilcox, CM, 1997) |
| "Thalidomide has been advocated as the treatment of choice for recalcitrant aphthae." | 7.69 | Thalidomide-resistant HIV-associated aphthae successfully treated with granulocyte colony-stimulating factor. ( Kostman, JR; Manders, SM; Mendez, L; Russin, VL, 1995) |
| "Pomalidomide is a safe and active chemotherapy-sparing agent for the treatment of KS among individuals with or without HIV." | 7.11 | Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection. ( George, J; Goncalves, P; Lurain, K; Polizzotto, MN; Ramaswami, R; Steinberg, SM; Uldrick, TS; Whitby, D; Widell, A; Wyvill, KM; Yarchoan, R, 2022) |
| "The case of an HIV-infected man in whom multiple myeloma was diagnosed following progressive anemia and fatigue is described." | 6.42 | Thalidomide-based treatment for HIV-associated multiple myeloma: a case report. ( Aboulafia, DM, 2003) |
| "Thalidomide has been used as a treatment for various human immunodeficiency virus (HIV)-associated and non-HIV-associated illnesses, generally in cases in which inflammatory disease is refractory to standard therapy." | 5.35 | Thalidomide treatment for refractory HIV-associated colitis: a case series. ( Hay, PE; Jarvis, JN; Johnson, L; Wilkins, EG, 2008) |
| "Thalidomide is an experimental drug currently used for oral aphthous ulcers and wasting syndrome, and is the same drug associated with severe fetal abnormalities in the 1960s." | 5.30 | Thalidomide shows benefit for microsporidial diarrhea. ( Bartnof, HS, 1997) |
| "To evaluate safety and efficacy of thalidomide in the treatment of prurigo nodularis in a group of human immunodeficiency virus (HIV)-infected patients whose condition was recalcitrant to standard treatment." | 5.11 | Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. ( Berger, T; Maurer, T; Poncelet, A, 2004) |
| "A multicenter, double-blind, randomized, placebo-controlled clinical trial was conducted to determine the safety and efficacy of thalidomide for treating esophageal aphthous ulceration in persons infected with human immunodeficiency virus (HIV)." | 5.09 | Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group. ( Basgoz, N; Chernoff, M; Fahey, JL; Fox, L; Hooton, TM; Jackson, JB; Jacobson, JM; MacPhail, LA; Sha, BE; Shikuma, CM; Simpson, DM; Spritzler, J; Trapnell, CB; Wohl, DA; Wu, AW, 1999) |
| "Thalidomide appears to be highly effective for oropharyngeal apthous ulcers in HIV-infected patients." | 5.08 | A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers. ( Alexander, LN; Wilcox, CM, 1997) |
| "A phase II trial is beginning using thalidomide as a treatment for chronic diarrhea in HIV-infected patients." | 5.08 | Thalidomide for diarrhea. ( , 1996) |
| "Thalidomide therapy has been shown to cause increases in body weight in patients with HIV and tuberculosis infections." | 5.08 | The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. ( Diakun, J; Freedman, VH; Haslett, P; Hempstead, M; Kaplan, G; Seidman, C; Vasquez, D, 1997) |
| "Celgene Corporation initiated a phase II safety and efficacy trial for Synovir (thalidomide) in the treatment of chronic intractable diarrhea in HIV-positive patients." | 5.08 | Thalidomide used to treat chronic diarrhea in HIV-positive patients. ( , 1996) |
| "An interim analysis of data from a NIAID-supported study determined that thalidomide effectively and safely heals severe mouth ulcers in persons with HIV infection." | 5.08 | Thalidomide effective treatment for AIDS-related mouth ulcers. ( Randall, P, 1995) |
| "A population pharmacokinetic (PPK) model to describe the pharmacokinetics of thalidomide in different patient populations was developed using data pooled from healthy subjects and patients with Hansen's disease, human immunodeficiency virus (HIV), and multiple myeloma (MM)." | 3.96 | Population Pharmacokinetic Model to Assess the Impact of Disease State on Thalidomide Pharmacokinetics. ( Chen, N; Gaudy, A; Hwang, R; Palmisano, M, 2020) |
| "Thalidomide has anti-inflammatory properties and shows promise for treating a variety of infectious and autoimmune diseases, but it must be used with strict precautions." | 3.70 | Thalidomide's tightly controlled "comeback". ( Calabrese, LH, 1999) |
| "Thalidomide has been advocated as the treatment of choice for recalcitrant aphthae." | 3.69 | Thalidomide-resistant HIV-associated aphthae successfully treated with granulocyte colony-stimulating factor. ( Kostman, JR; Manders, SM; Mendez, L; Russin, VL, 1995) |
| " Others report on the use of thalidomide or IL-10 for curtailing or suppressing tumor necrosis factor alpha in coincident HIV and tuberculosis patients." | 3.69 | Or is it the host, sir? ( Mascolini, M, 1996) |
| "Pomalidomide is a safe and active chemotherapy-sparing agent for the treatment of KS among individuals with or without HIV." | 3.11 | Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection. ( George, J; Goncalves, P; Lurain, K; Polizzotto, MN; Ramaswami, R; Steinberg, SM; Uldrick, TS; Whitby, D; Widell, A; Wyvill, KM; Yarchoan, R, 2022) |
| " Initial dosage level was 5 mg once per day for 21 days per 28-day cycle, with a de-escalated level of 3 mg if not tolerable, and aspirin 81 mg once per day thromboprophylaxis." | 2.82 | Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study. ( Aleman, K; Bevans, M; Figg, WD; Goncalves, PH; Khetani, V; Maldarelli, F; Marshall, V; Peer, CJ; Polizzotto, MN; Sereti, I; Steinberg, SM; Uldrick, TS; Whitby, D; Wyvill, KM; Yarchoan, R; Zeldis, JB, 2016) |
| "Thalidomide has increasing clinical benefits, including the healing of aphthous ulcers in patients with HIV." | 2.70 | Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251. AIDS Clinical Trials Group. ( Aweeka, F; Bellibas, SE; Chernoff, M; Jacobson, J; Jayewardene, A; Lizak, P; Spritzler, J; Trapnell, C, 2001) |
| "Thalidomide in lower intermittent doses is ineffective at preventing recurrence of aphthous ulcers in HIV-infected persons." | 2.70 | Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers. ( Chernoff, M; Fahey, JL; Fox, L; Greenspan, JS; Hooton, TM; Jackson, JB; Jacobson, JM; Pulvirenti, JJ; Shikuma, C; Spritzler, J; Wohl, DA, 2001) |
| " The safety, tolerability, and pharmacokinetics of a formulation of thalidomide with improved bioavailability in HIV-infected persons was examined in a placebo-controlled, dose-escalating phase 1 study." | 2.70 | Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267. ( Aweeka, FT; Bell, D; Cherng, DW; Fox, L; Holohan, MK; Kaplan, G; Pomerantz, R; Robinson, W; Schmitz, J; Simpson, D; Spritzler, J; Teppler, H; Thomas, S; Wohl, DA, 2002) |
| " Patients were orally dosed with 100 mg of thalidomide/day for 8 weeks." | 2.70 | Thalidomide is distributed into human semen after oral dosing. ( Burke, AB; Harden, JL; Johnson, MA; Noormohamed, FH; Peters, BS; Stirling, DI; Teo, SK; Thomas, SD; Youle, M, 2001) |
| " The drug was rapidly absorbed, with a mean absorption half-life of 0." | 2.69 | Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. ( Hawkins, DA; Higgs, CJ; Kook, KA; Lant, AF; Noormohamed, FH; Thomas, SD; Youle, MS, 1999) |
| "14 microg/ml in the 100- and 300-mg dosing groups, respectively, and the mean elimination half-life was approximately 6 h." | 2.68 | Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients. ( Figg, WD; Hahn, B; Kelly, G; Piscitelli, SC; Thomas, S; Walker, RE, 1997) |
| " Thalidomide, at the dosage used in this study, had no effect on peripheral CD4+ T cells nor on HIV viral burden in PBMC." | 2.68 | Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. ( Arroyo-Figueroa, H; Calva, JJ; Martínez del Cerro, V; Pasquetti, A; Reyes-Terán, G; Ruiz-Palacios, GM; Sierra-Madero, JG, 1996) |
| "Thalidomide has been reported to be an effective therapy for painful oral (mouth) ulcerations associated with AIDS that do not respond to the usual treatment options available." | 2.68 | Thalidomide: an alternative therapy for treatment of apthous ulcers (canker sores). ( Manesis, DA, 1995) |
| "Psoriasis is a systemic inflammatory disorder, associated with both physical and psychological burden, and can be the presenting feature of HIV infection." | 2.58 | HIV-Associated Psoriasis. ( Queirós, N; Torres, T, 2018) |
| "Hypertrophic genital herpes is a disfiguring manifestation of a common infection seen in immunocompromised hosts that can be clinically mistaken for malignancy." | 2.44 | Thalidomide therapy for the treatment of hypertrophic herpes simplex virus-related genitalis in HIV-infected individuals. ( Bergin, C; Holmes, A; McMenamin, M; Mulcahy, F, 2007) |
| "The case of an HIV-infected man in whom multiple myeloma was diagnosed following progressive anemia and fatigue is described." | 2.42 | Thalidomide-based treatment for HIV-associated multiple myeloma: a case report. ( Aboulafia, DM, 2003) |
| "Thalidomide has recently shown considerable promise in the treatment of a number of conditions, such as leprosy and cancer." | 2.41 | Immunological effects of thalidomide and its chemical and functional analogs. ( Dalgleish, AG; Dredge, K; Marriott, JB, 2002) |
| "Aphthous ulcers are among the most common oral lesions in the general population, with a frequency of up to 25% and three-month recurrence rates as high as 50%." | 2.41 | Treatment strategies for recurrent oral aphthous ulcers. ( Barrons, RW, 2001) |
| "Thalidomide was originally marketed as a sedative, but was removed from the market in 1961 after it was associated with an epidemic of severe birth defects." | 2.41 | Thalidomide in gastrointestinal disorders. ( Bousvaros, A; Mueller, B, 2001) |
| "The thalidomide product is a racemic mixture of the L- and D-enantiomeric forms of a synthetic glutamic acid derivative that contains a phthalimide ring and a glutarimide ring." | 2.41 | Thalidomide: a remarkable comeback. ( Jacobson, JM, 2000) |
| "Thalidomide has been used successfully in several other dermatologic disorders, including aphthous stomatitis, Behcet's syndrome, chronic cutaneous systemic lupus erythematosus, and graft-versus-host disease, the apparent shared characteristic of which is immune dysregulation." | 2.41 | Thalidomide: an antineoplastic agent. ( Amato, RJ, 2002) |
| "Thalidomide was evaluated for its in vitro activity against Encephalitozoon species by using the MRC-5 cell system." | 2.40 | Lack of in vitro antimicrosporidian activity of thalidomide. ( Drancourt, M; Ridoux, O, 1999) |
| "Thalidomide has shown potential in treating some AIDS-related conditions [cachexia (weight loss and muscle wasting), and aphtous oral, oesophageal or genital ulcers]." | 2.40 | New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide. ( Lisziewicz, J; Lori, F; Ravot, E, 1999) |
| " Recently, apremilast, a selective inhibitor of phosphodiesterase E4 has been suggested to be a safe and effective therapeutic option in HIV-infected population with psoriatic arthritis." | 1.51 | Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections. ( Bianchi, L; Campione, E; Esposito, M; Giunta, A; Manfreda, V, 2019) |
| "Thalidomide is a teratogenic drug which is known to inhibit angiogenesis and effectively inhibit cancer metastasis, yet the specific cellular targets for its effect are not well known." | 1.48 | CUL5 is required for thalidomide-dependent inhibition of cellular proliferation. ( Burnatowska-Hledin, MA; Dean, S; DeBruine, ZJ; Grossens, D; Hledin, MP; Kunkler, B; Madden, J; Marquez, GA; Ploch, C; Salamango, D; Schnell, A; Short, M, 2018) |
| "Thalidomide has been used as a treatment for various human immunodeficiency virus (HIV)-associated and non-HIV-associated illnesses, generally in cases in which inflammatory disease is refractory to standard therapy." | 1.35 | Thalidomide treatment for refractory HIV-associated colitis: a case series. ( Hay, PE; Jarvis, JN; Johnson, L; Wilkins, EG, 2008) |
| " The median daily thalidomide dosage was 100 mg and the median duration of drug treatment was 16 weeks." | 1.34 | A retrospective analysis of thalidomide therapy in non-HIV-related Kaposi's sarcoma. ( Ben M'barek, L; Biet, I; Fardet, L; Kérob, D; Lebbe, C; Mebazaa, A; Morel, P; Thervet, E, 2007) |
| "Thalidomide has significant immunomodulatory properties and has been used successfully in the treatment of oral ulcers and wasting in HIV patients." | 1.31 | Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro. ( Dalgleish, AG; Dransfield, I; Guckian, M; Hay, P, 2000) |
| "Of the 94 patients 50% had an AIDS diagnosis." | 1.30 | Severe oral ulceration in patients with HIV infection: a case series. ( Robinson, P; Williams, IG; Zakrzewska, JM, 1997) |
| "Thalidomide is an experimental drug currently used for oral aphthous ulcers and wasting syndrome, and is the same drug associated with severe fetal abnormalities in the 1960s." | 1.30 | Thalidomide shows benefit for microsporidial diarrhea. ( Bartnof, HS, 1997) |
| "Thalidomide is a drug associated with devastating side effects." | 1.30 | Thalidomide's long and winding road. ( Hanna, L, 1998) |
| "Thalidomide trials have been slow to recruit, therefore buyers clubs are working to make the drug available through their services." | 1.29 | Thalidomide and HIV: several possible uses. ( Smith, D, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.79) | 18.7374 |
| 1990's | 58 (45.67) | 18.2507 |
| 2000's | 38 (29.92) | 29.6817 |
| 2010's | 23 (18.11) | 24.3611 |
| 2020's | 7 (5.51) | 2.80 |
| Authors | Studies |
|---|---|
| Ramaswami, R | 2 |
| Polizzotto, MN | 2 |
| Lurain, K | 2 |
| Wyvill, KM | 2 |
| Widell, A | 2 |
| George, J | 2 |
| Goncalves, P | 1 |
| Steinberg, SM | 2 |
| Whitby, D | 2 |
| Uldrick, TS | 3 |
| Yarchoan, R | 3 |
| Romita, P | 1 |
| Foti, C | 1 |
| Calianno, G | 1 |
| Chiricozzi, A | 1 |
| Ne, E | 1 |
| Crespo, R | 1 |
| Izquierdo-Lara, R | 1 |
| Rao, S | 1 |
| Koçer, S | 1 |
| Górska, A | 1 |
| van Staveren, T | 1 |
| Kan, TW | 1 |
| van de Vijver, D | 1 |
| Dekkers, D | 1 |
| Rokx, C | 1 |
| Moulos, P | 1 |
| Hatzis, P | 1 |
| Palstra, RJ | 1 |
| Demmers, J | 1 |
| Mahmoudi, T | 1 |
| Qin, BE | 1 |
| Yuan, D | 1 |
| Xu, XF | 1 |
| Su, Z | 1 |
| Gu, M | 1 |
| Dai, K | 1 |
| Peng, FH | 1 |
| Jiang, Y | 1 |
| Gaudy, A | 1 |
| Hwang, R | 1 |
| Palmisano, M | 1 |
| Chen, N | 1 |
| Kwon, HY | 1 |
| Han, YJ | 1 |
| Im, JH | 1 |
| Baek, JH | 1 |
| Lee, JS | 1 |
| Mangusan, R | 1 |
| Ekwede, I | 1 |
| Ambinder, R | 1 |
| Cheever, M | 1 |
| Gulley, JL | 1 |
| Goncalves, PH | 2 |
| Wang, HW | 1 |
| Lomas, OC | 1 |
| Streetly, M | 1 |
| Pratt, G | 1 |
| Cavet, J | 1 |
| Royston, D | 1 |
| Schey, S | 1 |
| Ramasamy, K | 1 |
| Reddy, SP | 2 |
| Shah, VV | 1 |
| Wu, JJ | 2 |
| Vignesh, R | 1 |
| Shankar, EM | 1 |
| Queirós, N | 1 |
| Torres, T | 1 |
| Kunkler, B | 1 |
| Salamango, D | 1 |
| DeBruine, ZJ | 1 |
| Ploch, C | 1 |
| Dean, S | 1 |
| Grossens, D | 1 |
| Hledin, MP | 1 |
| Marquez, GA | 1 |
| Madden, J | 1 |
| Schnell, A | 1 |
| Short, M | 1 |
| Burnatowska-Hledin, MA | 1 |
| Sacchelli, L | 1 |
| Patrizi, A | 1 |
| Ferrara, F | 1 |
| Bardazzi, F | 1 |
| Balasko, A | 1 |
| Keynan, Y | 1 |
| Manfreda, V | 1 |
| Esposito, M | 1 |
| Campione, E | 1 |
| Bianchi, L | 1 |
| Giunta, A | 1 |
| Lee, E | 1 |
| Agrawal, S | 1 |
| Deshpande, A | 1 |
| Sbidian, E | 1 |
| Battistella, M | 1 |
| Legoff, J | 1 |
| Lafaurie, M | 1 |
| Bézier, M | 1 |
| Agbalika, F | 1 |
| Simon, F | 1 |
| Bouscarat, F | 1 |
| Cayuela, JM | 1 |
| Carcelain, G | 1 |
| Houhou, N | 1 |
| Bagot, M | 1 |
| Molina, JM | 2 |
| Janier, M | 1 |
| Bachelez, H | 1 |
| Fourcade, C | 1 |
| Mauboussin, JM | 1 |
| Lechiche, C | 1 |
| Lavigne, JP | 1 |
| Sotto, A | 1 |
| Charles, P | 1 |
| Richaud, C | 1 |
| Beley, S | 1 |
| Bodard, L | 1 |
| Simon, M | 1 |
| Sharma, S | 1 |
| Chandra, J | 1 |
| Gupta, R | 1 |
| Chauhan, R | 1 |
| Pourcher, V | 1 |
| Desnoyer, A | 1 |
| Assoumou, L | 1 |
| Lebbe, C | 3 |
| Curjol, A | 1 |
| Marcelin, AG | 1 |
| Cardon, F | 1 |
| Gibowski, S | 1 |
| Salmon, D | 1 |
| Chennebault, JM | 1 |
| Poizot-Martin, I | 1 |
| Peytavin, G | 1 |
| Boué, F | 1 |
| Costagliola, D | 1 |
| Gui, L | 1 |
| He, XH | 1 |
| Liu, P | 1 |
| Yang, JL | 1 |
| Qin, Y | 1 |
| Zhou, SY | 1 |
| Yang, S | 1 |
| Zhang, CG | 1 |
| Shi, YK | 1 |
| Aleman, K | 1 |
| Peer, CJ | 1 |
| Bevans, M | 1 |
| Sereti, I | 1 |
| Maldarelli, F | 1 |
| Marshall, V | 1 |
| Khetani, V | 1 |
| Figg, WD | 3 |
| Zeldis, JB | 1 |
| Stary, G | 1 |
| Kohrgruber, N | 1 |
| Herneth, AM | 1 |
| Gaiger, A | 1 |
| Stingl, G | 1 |
| Rieger, A | 1 |
| Tebruegge, M | 1 |
| Pantazidou, A | 1 |
| Bunn, MR | 1 |
| Blum, S | 1 |
| Cavassini, M | 1 |
| Lambert, JF | 1 |
| Fayet, A | 1 |
| Schapira, M | 1 |
| Jotterand, M | 1 |
| Bibas, M | 1 |
| Grisetti, S | 1 |
| Alba, L | 1 |
| Picchi, G | 1 |
| Del Nonno, F | 1 |
| Antinori, A | 1 |
| Passeron, T | 1 |
| De Keersmaecker, B | 1 |
| Allard, SD | 1 |
| Lacor, P | 1 |
| Schots, R | 1 |
| Thielemans, K | 1 |
| Aerts, JL | 1 |
| Lim, H | 1 |
| Kane, L | 1 |
| Schwartz, JB | 1 |
| Hesdorffer, CS | 1 |
| Deeks, SG | 1 |
| Greig, N | 1 |
| Ferrucci, L | 1 |
| Goetzl, EJ | 1 |
| Ramos, JM | 1 |
| Masiá, M | 1 |
| Durán, R | 1 |
| Gutiérrez, F | 1 |
| Baidas, S | 1 |
| Tfayli, A | 1 |
| Bhargava, P | 1 |
| Teo, S | 1 |
| Noormohamed, F | 1 |
| Youle, M | 2 |
| Johnson, M | 1 |
| Peters, B | 1 |
| Stirling, D | 1 |
| Thomas, S | 3 |
| Haslett, PA | 3 |
| Hanekom, WA | 2 |
| Muller, G | 1 |
| Kaplan, G | 8 |
| Dredge, K | 1 |
| Marriott, JB | 2 |
| Dalgleish, AG | 3 |
| Aboulafia, DM | 2 |
| Pantanowitz, L | 2 |
| Dezube, BJ | 2 |
| Jung, CP | 1 |
| Emmerich, B | 1 |
| Goebel, FD | 1 |
| Bogner, JR | 1 |
| Cisteró, B | 1 |
| Sala, M | 1 |
| Soler, A | 1 |
| García, N | 1 |
| Franks, ME | 1 |
| Macpherson, GR | 1 |
| Maurer, T | 1 |
| Poncelet, A | 1 |
| Berger, T | 1 |
| Baranda, L | 1 |
| Layseca-Espinosa, E | 1 |
| Abud-Mendoza, C | 1 |
| González-Amaro, R | 1 |
| Sharma, NL | 1 |
| Mahajan, VK | 1 |
| Sharma, VC | 1 |
| Sarin, S | 1 |
| Sharma, RC | 1 |
| Holmes, A | 1 |
| McMenamin, M | 1 |
| Mulcahy, F | 1 |
| Bergin, C | 1 |
| Ben M'barek, L | 1 |
| Fardet, L | 1 |
| Mebazaa, A | 1 |
| Thervet, E | 1 |
| Biet, I | 1 |
| Kérob, D | 1 |
| Morel, P | 2 |
| Johnson, L | 1 |
| Jarvis, JN | 1 |
| Wilkins, EG | 1 |
| Hay, PE | 1 |
| Manders, SM | 1 |
| Kostman, JR | 1 |
| Mendez, L | 1 |
| Russin, VL | 1 |
| Berger, TG | 1 |
| Hoffman, C | 1 |
| Thieberg, MD | 1 |
| Sire, S | 1 |
| Fraisse, P | 1 |
| Rey, D | 1 |
| Jacquemin, C | 1 |
| Kempf, G | 1 |
| Partisani, M | 1 |
| Lang, JM | 1 |
| Paterson, DL | 1 |
| Georghiou, PR | 2 |
| Allworth, AM | 1 |
| Kemp, RJ | 2 |
| Couderc, LJ | 1 |
| Mathez, D | 1 |
| Leibowitch, J | 1 |
| Autran, B | 1 |
| Caubarrere, I | 1 |
| Henriquet, F | 1 |
| Roy, MT | 1 |
| Repetto, T | 1 |
| Fusco, F | 1 |
| Oldfield, EC | 1 |
| Vosgerau, JC | 1 |
| Bodokh, I | 1 |
| Lacour, JP | 1 |
| Rainero, C | 1 |
| Castanet, J | 1 |
| Michiels, JF | 1 |
| Ortonne, JP | 1 |
| Makonkawkeyoon, S | 3 |
| Limson-Pobre, RN | 1 |
| Moreira, AL | 1 |
| Schauf, V | 1 |
| Pizarro, A | 1 |
| Pinilla, J | 1 |
| García-Tobaruela, A | 1 |
| Schuler, U | 1 |
| Ehninger, G | 1 |
| Klausner, JD | 3 |
| Akarasewi, P | 1 |
| Nakata, K | 1 |
| Kasinrerk, W | 1 |
| Corral, L | 1 |
| Dewar, RL | 1 |
| Lane, HC | 1 |
| Freedman, VH | 2 |
| Solèr, RA | 2 |
| Migliorati, C | 1 |
| van Waes, H | 1 |
| Nadal, D | 2 |
| Weidle, PJ | 1 |
| Minor, JR | 1 |
| Piscitelli, SC | 2 |
| Harry, TC | 1 |
| Louvel, D | 1 |
| Musso, S | 1 |
| Métivier, S | 1 |
| Croizet, O | 1 |
| Rouquet, RM | 1 |
| Massip, P | 1 |
| Escourrou, J | 1 |
| Frexinos, J | 1 |
| Howard, M | 1 |
| Brink, NS | 1 |
| Gibb, D | 1 |
| Tedder, RS | 1 |
| Reyes-Terán, G | 1 |
| Sierra-Madero, JG | 1 |
| Martínez del Cerro, V | 1 |
| Arroyo-Figueroa, H | 1 |
| Pasquetti, A | 1 |
| Calva, JJ | 1 |
| Ruiz-Palacios, GM | 1 |
| Alexander, LN | 1 |
| Wilcox, CM | 1 |
| Haslett, P | 2 |
| Tramontana, J | 1 |
| Burroughs, M | 1 |
| Hempstead, M | 2 |
| Seidman, C | 1 |
| Diakun, J | 1 |
| Vasquez, D | 1 |
| Birnkrant, D | 1 |
| Sharp, M | 1 |
| Getty, J | 1 |
| Hahn, B | 1 |
| Kelly, G | 1 |
| Walker, RE | 1 |
| Zakrzewska, JM | 1 |
| Robinson, P | 1 |
| Williams, IG | 1 |
| Di Fabio, S | 1 |
| Trabattoni, D | 2 |
| Geraci, A | 1 |
| Ruzzante, S | 1 |
| Panzini, G | 1 |
| Fusi, ML | 2 |
| Chiarotti, F | 1 |
| Corrias, F | 1 |
| Belli, R | 1 |
| Verani, P | 1 |
| Dalgleish, A | 1 |
| Clerici, M | 2 |
| Titti, F | 1 |
| Larkin, M | 1 |
| Calabrese, LH | 1 |
| Jacobson, JM | 3 |
| Spritzler, J | 4 |
| Fox, L | 3 |
| Fahey, JL | 2 |
| Jackson, JB | 2 |
| Chernoff, M | 3 |
| Wohl, DA | 3 |
| Wu, AW | 1 |
| Hooton, TM | 2 |
| Sha, BE | 1 |
| Shikuma, CM | 1 |
| MacPhail, LA | 1 |
| Simpson, DM | 1 |
| Trapnell, CB | 1 |
| Basgoz, N | 1 |
| Noormohamed, FH | 2 |
| Youle, MS | 1 |
| Higgs, CJ | 1 |
| Kook, KA | 1 |
| Hawkins, DA | 1 |
| Lant, AF | 1 |
| Thomas, SD | 2 |
| Ridoux, O | 1 |
| Drancourt, M | 1 |
| Moreira, A | 1 |
| Metatratip, P | 1 |
| Boyle, B | 1 |
| Kunachiwa, W | 1 |
| Maneekarn, N | 1 |
| Vongchan, P | 1 |
| Corral, LG | 1 |
| Elbeik, T | 1 |
| Shen, Z | 1 |
| Miller, MT | 1 |
| Strömland, K | 1 |
| La Maestra, L | 1 |
| Zaninoni, A | 1 |
| Lazzarin, A | 1 |
| Barcellini, W | 1 |
| Shannon, E | 1 |
| Aseffa, A | 1 |
| Pankey, G | 1 |
| Sandoval, F | 1 |
| Lutz, B | 1 |
| Ravot, E | 1 |
| Lisziewicz, J | 1 |
| Lori, F | 1 |
| Calabrese, L | 1 |
| Fleischer, AB | 1 |
| Gori, A | 1 |
| Rossi, MC | 1 |
| Marchetti, G | 1 |
| Molteni, C | 1 |
| Franzetti1, F | 1 |
| Guckian, M | 1 |
| Dransfield, I | 1 |
| Hay, P | 1 |
| Neiger, BL | 1 |
| Greenspan, JS | 1 |
| Pulvirenti, JJ | 1 |
| Shikuma, C | 1 |
| Barrons, RW | 1 |
| Fu, CS | 1 |
| Conteas, CN | 1 |
| LaRiviere, MJ | 1 |
| Manesis, DA | 1 |
| Smith, D | 1 |
| Baker, R | 1 |
| Randall, P | 1 |
| Mascolini, M | 1 |
| MacDougall, DS | 3 |
| Bartnof, HS | 1 |
| Hanna, L | 1 |
| Bousvaros, A | 1 |
| Mueller, B | 1 |
| Dolev, E | 1 |
| Krown, SE | 1 |
| Teo, SK | 1 |
| Harden, JL | 1 |
| Burke, AB | 1 |
| Johnson, MA | 1 |
| Peters, BS | 1 |
| Stirling, DI | 1 |
| Aweeka, F | 1 |
| Trapnell, C | 1 |
| Jayewardene, A | 1 |
| Bellibas, SE | 1 |
| Lizak, P | 1 |
| Jacobson, J | 1 |
| Hughes, J | 1 |
| Apolles, P | 1 |
| Ganiso, V | 1 |
| Allin, R | 1 |
| Goddard, E | 1 |
| Hussey, GD | 1 |
| Tuinmann, G | 1 |
| Hegewisch-Becker, S | 1 |
| Hossfeld, DK | 1 |
| Taiwo, BO | 1 |
| Amato, RJ | 1 |
| Aweeka, FT | 1 |
| Schmitz, J | 1 |
| Pomerantz, R | 1 |
| Cherng, DW | 1 |
| Simpson, D | 1 |
| Bell, D | 1 |
| Holohan, MK | 1 |
| Robinson, W | 1 |
| Teppler, H | 1 |
| Strazzi, S | 1 |
| Geoffray, C | 1 |
| Ablon, G | 1 |
| Verola, O | 1 |
| Samson, J | 2 |
| Kuffer, R | 2 |
| Radeff, B | 2 |
| Günzler, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Study of the Safety, Pharmacokinetics and Efficacy of Pomalidomide (CC-4047) in the Treatment of Kaposi Sarcoma in Individuals With or Without HIV[NCT01495598] | Phase 1/Phase 2 | 28 participants (Actual) | Interventional | 2012-01-10 | Completed | ||
| The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study[NCT04273529] | Phase 2 | 100 participants (Anticipated) | Interventional | 2020-02-20 | Not yet recruiting | ||
| The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study[NCT04273581] | Phase 2 | 40 participants (Anticipated) | Interventional | 2020-02-18 | Not yet recruiting | ||
| Multicenter, Open Label, Phase II Trial to Evaluate the Efficacy and Safety of Treatment With Lenalidomide in Kaposi Disease Associated With HIV Infection (ANRS 154/LENAKAP)[NCT01282047] | Phase 2 | 12 participants (Actual) | Interventional | 2011-10-31 | Terminated | ||
| Study of Pomalidomide in Anal Cancer Precursors (SPACE): a Phase 2 Study of Immunomodulation in People With Persistent HPV-associated High Grade Squamous Intraepithelial Lesions[NCT03113942] | Phase 2 | 26 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
| Pharmacologic T Cell Costimulation In HIV Disease[NCT00053430] | Phase 2 | 40 participants (Actual) | Interventional | 2001-04-30 | Completed | ||
| A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus[NCT00001680] | Phase 2 | 17 participants | Interventional | 1997-10-31 | Completed | ||
| [NCT00004276] | Phase 2 | 50 participants | Interventional | 1990-09-30 | Completed | ||
| Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection[NCT00000790] | Phase 2 | 164 participants | Interventional | Completed | |||
| A Randomized Phase II Study of the Safety, Immunologic, and Virologic Effects of Cyclosporine A in Conjunction With Trizivir(R) and Kaletra(R) Versus Trizivir(R) and Kaletra(R) Alone During Primary HIV-1 Infection[NCT00084149] | Phase 2 | 54 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection[NCT00000812] | Phase 1 | 36 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
KSHV viral load in peripheral blood mononuclear cells was assessed by modifying a sandwich enzyme-linked immunosorbent assay (ELISA). Viral load testing may provide useful information on the occurrence of KSHV replication. Undetectable levels is good. (NCT01495598)
Timeframe: Baseline to 4 weeks, baseline to 8 weeks and baseline to end of treatment
| Intervention | copies per million PBMC (Median) |
|---|---|
| Baseline to 4 Weeks | 0 |
| Baseline to 8 Weeks | 0 |
| Baseline to End of Treatment | 0 |
HIV viral load in peripheral blood mononuclear cells was assessed by quantitative real-time polymerase chain reaction (PCR). The lower limit of detection for HIV viral load is <50 copies mL. (NCT01495598)
Timeframe: Baseline to 4 weeks, baseline to 8 weeks and baseline to end of treatment
| Intervention | Copies/mL (Median) |
|---|---|
| Baseline to 4 Weeks | 0 |
| Baseline to 8 Weeks | 0 |
| Baseline to End of Treatment | 0 |
"A dose limiting toxicity is any grade 4 toxicity not including lymphopenia, cluster of differentiation 4 (CD4) lymphopenia, neutropenia, anemia and bilirubin or creatine kinase (CK) elevation that is at least possibly due to pomalidomide and is not attributable to human immunodeficiency virus (HIV), its therapy or Kaposi Sarcoma (KS). Any grade 3 toxicity that is at least possibly due to pomalidomide and is not attributable to HIV, its therapy, or KS and restrictions such as grade 3 thrombocytopenia if grade 3 for 14 days or more, Grade 3 asymptomatic hyperuricemia or hypophosphatemia, or Grade 3 amylase elevations.~Any arterial or deep venous thromboembolic event or a second superficial thromboembolic event that is at least possibly due to pomalidomide. Inability to deliver pomalidomide on at least 50% of scheduled days during the first two cycles of therapy as a result of toxicity that is probably or definitely attributable to pomalidomide." (NCT01495598)
Timeframe: First 8 weeks (2 cycles) of drug administration
| Intervention | toxicities (Number) |
|---|---|
| All Participants - Pomalidomide 5mg Daily | 0 |
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01495598)
Timeframe: Date treatment consent signed to date off study, approximately 124 months and 1 day.
| Intervention | Participants (Count of Participants) |
|---|---|
| All Participants - Pomalidomide 5mg Daily | 28 |
PFS is defined as time from day 1 of pomalidomide therapy until progression requiring a change in therapy, estimated using the Kaplan-Meier method. Progression was assessed using the Modified Acquired Immunodeficiency Syndrome (AIDS) Clinical Trials Group criteria. Progressive disease (PD) involved a 25% or greater increase in total lesions, nodular lesion, or area of the five indicator lesions. (NCT01495598)
Timeframe: time from day 1 of pomalidomide therapy until progression requiring a change in therapy, an average of 9.97 months
| Intervention | months (Median) |
|---|---|
| All Participants | 10.2 |
| HIV Positive Participants | 10.3 |
| HIV Negative Participants | 9.4 |
Antitumor effect of pomalidomide was assessed at the established tolerated dose after a first course of pomalidomide. Kaposi sarcoma responses were assessed using the Modified Acquired Immunodeficiency Syndrome (AIDS) Clinical Trials Group criteria. Complete Response (CR) required clinical resolution of all lesions and tumor-associated phenomenon with biopsy confirmation. Clinical Complete Response (cCR) is resolution of all lesions except for some residual pigmentation but who did not have a biopsy of a representative pigmented area. Partial Response (PR) required ≥ 50% decrease in the number of lesions and/or sum product of the diameters of marker lesions and/or nodularity of lesions, and no new lesions in previously uninvolved areas or criteria. Stable Disease (SD) was assessed for all participants who did not meet criteria doe CR, PR, or PD. And progressive disease (PD) involved a 25% or greater increase in total lesions, nodular lesion, or area of the five indicator lesions. (NCT01495598)
Timeframe: After completion of 2 cycles of therapy up to 48 weeks
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Complete Response (CR) | Clinical Complete Response (CCR) | Partial Response (PR) | Stable Disease (SD) | Progressive Disease (PD) | |
| All Participants - Pomalidomide 5mg Daily | 1 | 3 | 16 | 5 | 3 |
Antitumor effect of pomalidomide was assessed at the established tolerated dose after a second course of pomalidomide. Kaposi sarcoma responses were assessed using the Modified Acquired Immunodeficiency Syndrome (AIDS) Clinical Trials Group criteria. Complete Response (CR) required clinical resolution of all lesions and tumor-associated phenomenon with biopsy confirmation. Clinical Complete Response (cCR) is resolution of all lesions except for some residual pigmentation but who did not have a biopsy of a representative pigmented area. Partial Response (PR) required ≥ 50% decrease in the number of lesions and/or sum product of the diameters of marker lesions and/or nodularity of lesions, and no new lesions in previously uninvolved areas or criteria. Stable Disease (SD) was assessed for all participants who did not meet criteria doe CR, PR, or PD. And progressive disease (PD) involved a 25% or greater increase in total lesions, nodular lesion, or area of the five indicator lesions. (NCT01495598)
Timeframe: After completion of 2 cycles of therapy up to 48 weeks after the start of the second course of Pomalidomide
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Complete Response (CR) | Clinical Complete Response (CCR) | Partial Response (PR) | Stable Disease (SD) | Progressive Disease (PD) | |
| All Participants - Pomalidomide 5mg Daily | 0 | 0 | 2 | 2 | 0 |
AUC is a measure of the serum concentration of Pomalidomide over time. It is used to characterize drug absorption. The AUC extrapolated to infinity was used, unless the percent extrapolated exceeded 25% in which case AUC to the last quantifiable time point (AUCLast) was used. The steady-state exposure on Day 15 of cycle 1 was calculated using AUCLast. (NCT01495598)
Timeframe: At pre-dose, 1, 2, 3, 4, 6, and 8 hours after dose on Cycle 1 Day 1, and pre-dose, 1, 2, 3, 4, 6, 8, and 24 hours after dose on Cycle 1 Day 15.
| Intervention | hours*ng/ml (Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 1 Day 15 | |
| All Participants - Pomalidomide 5mg Daily | 567.3 | 805.3 |
Area under the plasma concentration versus time curve (AUC) was calculated using the log-linear trapezoidal method. The AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. (NCT01495598)
Timeframe: At pre-dose, 1, 2, 3, 4, 6, and 8 hours after dose on Cycle 1 Day 1, and pre-dose, 1, 2, 3, 4, 6, 8, and 24 hours after dose on Cycle 1 Day 15.
| Intervention | hours*ng/mL (Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 1 Day 15 | |
| All Participants - Pomalidomide 5mg Daily | 466.5 | 504.5 |
Cytokines were evaluated using MSD 96-Well Multiarray Proinflammatory 7-plex assay (MesoScale Discovery). (NCT01495598)
Timeframe: Baseline to 4 weeks, baseline to 8 weeks and baseline to end of treatment
| Intervention | pg/mL (Median) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Interferon gamma (ƴ) | Interleukin 4 (IL4) | Interleukin 6 (IL6) | Interleukin 8 (IL8) | Interleukin 10 (IL10) | Interleukin 12 (IL12) | Interleukin 13 (IL13) | Tumor necrosis factor alpha (TNFα) | Interferon (IFN)-inducible protein 10 (IP-10) | |
| Baseline to 4 Weeks | -0.3 | 0.07 | 0.4 | 71.9 | 0.1 | 0.02 | 0.7 | 0.3 | 76.5 |
| Baseline to 8 Weeks | -0.4 | 0.1 | 0.3 | 64.8 | -0.03 | 0.00 | 0.9 | 0.5 | 18.4 |
| Baseline to End of Treatment | -2.4 | 0.06 | 0.6 | 47.5 | -0.05 | 0.03 | 0.6 | 0.06 | -73.3 |
Fluorescence activated cell sorting. (NCT01495598)
Timeframe: Baseline to 4 weeks, baseline to 8 weeks, and baseline to end of treatment
| Intervention | cells/µL (Median) | ||||
|---|---|---|---|---|---|
| CD4+/All participants | CD4+ among HIV+ participants | CD8+/All participants | CD8+ among HIV+ participants | CD19+/All participants | |
| Baseline to 4 Weeks | 66.5 | 72 | 104.5 | 198 | -40 |
| Baseline to 8 Weeks | 37 | 37 | 115 | 129 | -55 |
| Baseline to End of Treatment | -54 | -14 | 73 | 75 | -75 |
Plasma decay half-life is the time measured for the plasma concentration of the drug to decrease by one half. (NCT01495598)
Timeframe: At pre-dose, 1, 2, 3, 4, 6, and 8 hours after dose on Cycle 1 Day 1, and pre-dose, 1, 2, 3, 4, 6, 8, and 24 hours after dose on Cycle 1 Day 15.
| Intervention | hours (Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 1 Day 15 | |
| All Participants - Pomalidomide 5mg Daily | 6.85 | 8.27 |
Plasma concentrations of pomalidomide were assayed using high-performance liquid chromatography with fluorescence detection with a lower limit of quantitation of 1 ng/mL and were recorded as observed values. A non-compartmental analysis was used to calculate plasma pharmacokinetic parameters (Pharsight, Mountain View, California). (NCT01495598)
Timeframe: At pre-dose, 1, 2, 3, 4, 6, and 8 hours after dose on Cycle 1 Day 1, and pre-dose, 1, 2, 3, 4, 6, 8, and 24 hours after dose on Cycle 1 Day 15.
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 1 Day 15 | |
| All Participants - Pomalidomide 5mg Daily | 53.1 | 59.0 |
The number of participants responding to each question with the indicated responses is shown. Changes in quality of life in participants receiving pomalidomide. HRQL was analyzed using a mixed-model repeated-measures analysis and the marginal homogeneity test for Kaposi sarcoma-specific questions. Three supplemental questions addressing pain, swelling, and satisfaction with physical appearance was used to collect quality of life data. (NCT01495598)
Timeframe: Baseline, timepoint 1: after 3 months of therapy, and timepoint 2: 1 month after completion of therapy
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Pain has interfered with my normal work or activities at baseline | Pain has interfered with my normal work or activities - timepoint 2: after 3 months of therapy | Pain has interfered with my normal work or activities timepoint 3:1month after completion of therapy | I am satisfied with my physical appearance at baseline | I am satisfied with my physical appearance - timepoint 2: after 3 months of therapy | I am satisfied with my physical appearance - timepoint 3: 1 month after completion of therapy | I have had swelling in my face, arms, or legs at baseline | I have had swelling in my face, arms, or legs - timepoint 2: after 3 months of therapy | I have had swelling in my face, arms, or legs - timepoint 3: 1 month after completion of therapy | |
| A Little Bit | 3 | 5 | 5 | 6 | 1 | 2 | 2 | 2 | 3 |
| Little or None* | 13 | 12 | 12 | 12 | 7 | 5 | 8 | 9 | 9 |
| Not At All | 10 | 7 | 7 | 6 | 6 | 3 | 6 | 7 | 6 |
| Quite a Bit | 5 | 1 | 1 | 3 | 5 | 8 | 4 | 4 | 5 |
| Somewhat | 2 | 5 | 4 | 6 | 5 | 5 | 5 | 4 | 4 |
| Somewhat or MoreϮ | 9 | 7 | 7 | 10 | 12 | 14 | 14 | 10 | 10 |
| Very Much | 2 | 1 | 2 | 1 | 2 | 1 | 5 | 2 | 1 |
Adverse events (AE's) that are possibly, probably, and/or definitely attributed to pomalidomide were assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Grade 1 is mild. Grade 2 is moderate. Grade 3 is severe. Grade 4 is life-threatening. (NCT01495598)
Timeframe: During each cycle and 4 weeks after completing therapy, with any continuing AE's observed until resolution, approximately 124 months and 1 day.
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low white cell count | Febrile neutropenia | Neutropenia | Lymphocytopenia | Anemia | Thrombocytopenia | Fatigue | Infection | Constipation | Nausea | Elevated alanine aminotransferase (ALT) | Impaired concentration | Depression | Hypothyroidism | Rash | Vasculitis | |
| Grade 1 | 21 | 0 | 24 | 13 | 16 | 16 | 17 | 0 | 18 | 10 | 7 | 3 | 1 | 3 | 18 | 0 |
| Grade 2 | 10 | 0 | 26 | 2 | 4 | 0 | 2 | 7 | 3 | 0 | 0 | 1 | 1 | 3 | 6 | 0 |
| Grade 3 | 1 | 1 | 14 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Grade 4 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The percentage of participants responding to each question with the indicated responses is shown. Changes in quality of life in participants receiving pomalidomide. HRQL was analyzed using a mixed-model repeated-measures analysis and the marginal homogeneity test for Kaposi sarcoma-specific questions. Three supplemental questions addressing pain, swelling, and satisfaction with physical appearance was used to collect quality of life data. (NCT01495598)
Timeframe: Baseline, timepoint 1: after 3 months of therapy, and timepoint 2: 1 month after completion of therapy
| Intervention | percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Pain has interfered with my normal work or activities at baseline | Pain has interfered with my normal work or activities - timepoint 2: after 3 months of therapy | Pain has interfered with my normal work or activities timepoint 3:1month after completion of therapy | I am satisfied with my physical appearance at baseline | I am satisfied with my physical appearance - timepoint 2: after 3 months of therapy | I am satisfied with my physical appearance - timepoint 3: 1 month after completion of therapy | I have had swelling in my face, arms, or legs at baseline | I have had swelling in my face, arms, or legs - timepoint 2: after 3 months of therapy | I have had swelling in my face, arms, or legs - timepoint 3: 1 month after completion of therapy | |
| A Little Bit | 13.6 | 26.3 | 26.3 | 27.3 | 4.5 | 10.5 | 9.1 | 10.5 | 15.8 |
| Little or None* | 59.1 | 63.2 | 63.2 | 54.6 | 36.8 | 26.3 | 36 | 47 | 47 |
| Not At All | 45.5 | 36.8 | 36.8 | 27.3 | 31.6 | 15.8 | 27.3 | 36.8 | 31.6 |
| Quite a Bit | 22.7 | 5.3 | 5.3 | 13.6 | 26.3 | 42.1 | 18.2 | 21.1 | 26.3 |
| Somewhat | 9.1 | 26.3 | 21.1 | 27.3 | 26.3 | 26.3 | 22.7 | 21.1 | 21.1 |
| Somewhat or MoreϮ | 40.9 | 36.8 | 36.8 | 45.4 | 63.2 | 73.7 | 63.6 | 52.6 | 52.6 |
| Very Much | 9.1 | 5.3 | 10.5 | 4.5 | 10.5 | 5.3 | 22.7 | 10.5 | 5.3 |
Changes in quality of life in participants receiving pomalidomide. HRQL was analyzed using a mixed-model repeated-measures analysis for FAHI and the marginal homogeneity test for Kaposi sarcoma-specific questions such as physical well-being (PWB), emotional well-being (EWB), functional and global well-being (FGWB), social well-being (SWB), and cognitive functioning (CF). The range of possible scores for each subscale was as follows: PWB and EWB, 0 to 40; FGWB, 0 to 52; SWB, 0 to 32; CF, 0 to 12. The total FAHI score, with possible scores ranging from 0 to 176, was calculated as the sum of all five subscale values, with higher scores indicating better results. Questionnaires completed at early withdrawal visits were not included in the analyses. (NCT01495598)
Timeframe: Baseline, after 3 months of therapy, and after completion of therapy, up to 48 weeks
| Intervention | score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| FAHI Total | Physical well-being | Emotional well-being | Functional and global well-being | Social well-being | Cognitive functioning | |
| After 3 Months of Therapy | 123.4 | 31.3 | 27.7 | 34.5 | 21.5 | 8.5 |
| After Completion of Therapy | 118. | 31.3 | 26.2 | 32.9 | 20.9 | 8.7 |
| Baseline | 123.0 | 30.8 | 25.1 | 34.4 | 22.1 | 9.1 |
Time to maximum observed serum concentration of Pomalidomide was reported. (NCT01495598)
Timeframe: At pre-dose, 1, 2, 3, 4, 6, and 8 hours after dose on Cycle 1 Day 1, and pre-dose, 1, 2, 3, 4, 6, 8, and 24 hours after dose on Cycle 1 Day 15.
| Intervention | hours (Median) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 1 day 15 | |
| All Participants - Pomalidomide 5mg Daily | 2.00 | 2.08 |
Grade 1-4 adverse events related to study medication (NCT00084149)
Timeframe: Up to 48 weeks
| Intervention | participants (Number) |
|---|---|
| Cyclosporine | 1 |
| No Cyclosporine | 0 |
(NCT00084149)
Timeframe: At Week 48
| Intervention | cells/mm^3 (Median) |
|---|---|
| Cyclosporine | 301 |
| No Cyclosporine | 287 |
(NCT00084149)
Timeframe: At Week 48
| Intervention | log10(copies/mL) (Mean) |
|---|---|
| Cyclosporine | 1.70 |
| No Cyclosporine | 1.70 |
(NCT00084149)
Timeframe: At 48 weeks after the start of treatment
| Intervention | log10(copies/mL) (Median) |
|---|---|
| Cyclosporine | 1.88 |
| No Cyclosporine | 1.92 |
(NCT00084149)
Timeframe: Week 48
| Intervention | Participants (Count of Participants) |
|---|---|
| Cyclosporine | 27 |
| No Cyclosporine | 13 |
(NCT00084149)
Timeframe: At Week 12
| Intervention | log10(copies/mL) (Median) |
|---|---|
| Cyclosporine | 2.22 |
| No Cyclosporine | 2.13 |
(NCT00084149)
Timeframe: At Week 24
| Intervention | log10(copies/mL) (Median) |
|---|---|
| Cyclosporine | 2.12 |
| No Cyclosporine | 1.96 |
24 reviews available for thalidomide and HIV Coinfection
| Article | Year |
|---|---|
HIV-Associated Psoriasis.
Topics: Adrenal Cortex Hormones; Biological Therapy; Contraindications, Drug; Diagnosis, Differential; Disea | 2018 |
Shedding light on IRIS: from Pathophysiology to Treatment of Cryptococcal Meningitis and Immune Reconstitution Inflammatory Syndrome in HIV-Infected Individuals.
Topics: Adrenal Cortex Hormones; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Clinical Tri | 2019 |
[What's new in dermatological research?].
Topics: Biomedical Research; Dermatitis, Atopic; Dermatology; Herpesviridae Infections; HIV Infections; Huma | 2010 |
Thalidomide: an old drug with new clinical applications.
Topics: Autoimmune Diseases; HIV Infections; Humans; Immunosuppressive Agents; Neoplasms; Skin Diseases; Tha | 2002 |
Immunological effects of thalidomide and its chemical and functional analogs.
Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Antiviral Agents; HIV Infections; Humans; Immune Sy | 2002 |
Thalidomide-based treatment for HIV-associated multiple myeloma: a case report.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Bone Marrow Examination; CD4 Lymph | 2003 |
Editorial comment: multiple myeloma and HIV infection--causal or casual coincidence?
Topics: Anti-HIV Agents; Causality; Diagnosis, Differential; HIV Infections; HIV-1; Humans; Immunosuppressiv | 2003 |
Thalidomide.
Topics: Clinical Trials as Topic; Gastrointestinal Diseases; HIV Infections; Humans; Neoplasms; Rheumatic Di | 2004 |
Plasma cell disorders in HIV-infected patients: from benign gammopathy to multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; HIV Infect | 2004 |
Thalidomide therapy for the treatment of hypertrophic herpes simplex virus-related genitalis in HIV-infected individuals.
Topics: Adult; Genitalia, Male; Herpes Genitalis; HIV Infections; Humans; Hypertrophy; Immunosuppressive Age | 2007 |
Thalidomide: rationale for renewed use in immunological disorders.
Topics: Bone Marrow Transplantation; Cell Adhesion Molecules; Female; HIV Infections; Humans; Immune System | 1995 |
Thalidomide for aphthous ulcers in patients infected with the human immunodeficiency virus.
Topics: Clinical Trials as Topic; HIV Infections; Humans; Immunosuppressive Agents; Stomatitis, Aphthous; Th | 1996 |
Thalidomide in diseases associated with human immunodeficiency virus infection.
Topics: HIV Infections; Humans; Immunosuppressive Agents; Thalidomide | 1996 |
Lack of in vitro antimicrosporidian activity of thalidomide.
Topics: AIDS-Related Opportunistic Infections; Analysis of Variance; Animals; Anti-HIV Agents; Dose-Response | 1999 |
Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses.
Topics: Eye Abnormalities; Female; History, 20th Century; HIV Infections; Humans; Infant, Newborn; Leprosy; | 1999 |
New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide.
Topics: Cyclosporine; HIV Infections; Humans; Hydroxyurea; Immunosuppressive Agents; Nucleic Acid Synthesis | 1999 |
Thalidomide: current and potential clinical applications.
Topics: Angiogenesis Inhibitors; Anti-HIV Agents; Arthritis, Rheumatoid; Behcet Syndrome; Dermatologic Agent | 2000 |
Treatment strategies for recurrent oral aphthous ulcers.
Topics: Adjuvants, Immunologic; Administration, Topical; Adrenal Cortex Hormones; Aminopyridines; Anti-Infla | 2001 |
Thalidomide: a remarkable comeback.
Topics: Angiogenesis Inhibitors; Animals; HIV Infections; Humans; Immunosuppressive Agents; Neoplasms; Thali | 2000 |
Thalidomide in gastrointestinal disorders.
Topics: Behcet Syndrome; Cell Adhesion; Colitis, Ulcerative; Crohn Disease; Gastrointestinal Diseases; Graft | 2001 |
[The thalidomide story and its lessons].
Topics: Abnormalities, Drug-Induced; Anti-HIV Agents; Antineoplastic Agents; Female; Germany; History, 20th | 2001 |
Management of Kaposi sarcoma: the role of interferon and thalidomide.
Topics: Antiviral Agents; Combined Modality Therapy; Cytokines; Disease Progression; HIV Infections; Humans; | 2001 |
[New indications for thalidomide?].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiogenesis Inhibitors; Animals; Anti-HIV Agents; A | 2001 |
Thalidomide: an antineoplastic agent.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; HIV Infections; H | 2002 |
24 trials available for thalidomide and HIV Coinfection
| Article | Year |
|---|---|
Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection.
Topics: Anticoagulants; Herpesvirus 8, Human; HIV Infections; Humans; Sarcoma, Kaposi; Thalidomide; Venous T | 2022 |
Phase II Trial of Lenalidomide in HIV-Infected Patients with Previously Treated Kaposi's Sarcoma: Results of the ANRS 154 Lenakap Trial.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Drug-Related Side Effects and Adverse Reactions; F | 2017 |
Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; HIV Infections; Humans; Male; Middle Age | 2016 |
Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; HIV Infections; Humans; Male; Middle Age | 2016 |
Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; HIV Infections; Humans; Male; Middle Age | 2016 |
Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; HIV Infections; Humans; Male; Middle Age | 2016 |
Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy.
Topics: Administration, Oral; Adult; Aged; Drug Administration Schedule; Female; HIV Infections; Humans; Imm | 2004 |
Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection.
Topics: Adult; HIV Infections; HIV-1; Humans; Male; Middle Aged; Recurrence; Retrospective Studies; Stomatit | 1995 |
The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection.
Topics: Adult; Body Weight; CD4 Lymphocyte Count; Double-Blind Method; HIV Infections; HIV-1; Humans; Immuno | 1996 |
Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial.
Topics: Adult; CD4 Lymphocyte Count; Cells, Cultured; Double-Blind Method; Female; Follow-Up Studies; HIV In | 1996 |
A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers.
Topics: Adult; Anti-Ulcer Agents; Esophageal Diseases; Follow-Up Studies; HIV Infections; Humans; Prospectiv | 1997 |
The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus.
Topics: Body Composition; Body Weight; Calorimetry; Cohort Studies; HIV Infections; Humans; Male; Nitrogen; | 1997 |
Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; HIV Infections; Human | 1997 |
Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antigens, CD; Double-Blind Method; Esophageal Diseases; E | 1999 |
Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects.
Topics: Administration, Oral; Adult; Blood Pressure; Cross-Over Studies; Half-Life; Heart Rate; HIV Infectio | 1999 |
Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Cytokines; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Hyperse | 1999 |
Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers.
Topics: Anti-HIV Agents; Double-Blind Method; HIV Infections; Humans; Immunosuppressive Agents; Recurrence; | 2001 |
Thalidomide: an alternative therapy for treatment of apthous ulcers (canker sores).
Topics: CD4 Lymphocyte Count; Double-Blind Method; HIV Infections; Humans; Placebos; Randomized Controlled T | 1995 |
Interleukin-2 studies.
Topics: Antibodies, Monoclonal; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Thera | 1995 |
Thalidomide for mouth ulcers and wasting.
Topics: Cachexia; Double-Blind Method; HIV Infections; Humans; Placebos; Stomatitis, Aphthous; Thalidomide | 1995 |
Thalidomide effective treatment for AIDS-related mouth ulcers.
Topics: Esophagus; HIV Infections; Humans; Placebos; Stomatitis, Aphthous; Thalidomide; Ulcer | 1995 |
Thalidomide used to treat chronic diarrhea in HIV-positive patients.
Topics: Cachexia; Diarrhea; Double-Blind Method; HIV Infections; Humans; Thalidomide; Treatment Outcome | 1996 |
Thalidomide for diarrhea.
Topics: Diarrhea; HIV Infections; Humans; Quality of Life; Thalidomide; Tumor Necrosis Factor-alpha; Weight | 1996 |
Thalidomide is distributed into human semen after oral dosing.
Topics: Administration, Oral; Angiogenesis Inhibitors; Double-Blind Method; Female; HIV Infections; Humans; | 2001 |
Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251. AIDS Clinical Trials Group.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Female; HIV Infections; Humans; Male; Middle Aged; Odds Ra | 2001 |
The immunomodulatory effects of thalidomide on human immunodeficiency virus-infected children.
Topics: Anti-HIV Agents; CD8-Positive T-Lymphocytes; Child, Preschool; Female; HIV Infections; HIV-1; Humans | 2001 |
Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Female; HIV Infections; Humans; M | 2002 |
79 other studies available for thalidomide and HIV Coinfection
| Article | Year |
|---|---|
Successful treatment with secukinumab in an HIV-positive psoriatic patient after failure of apremilast.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; HIV Infections; Human | 2022 |
Catchet-MS identifies IKZF1-targeting thalidomide analogues as novel HIV-1 latency reversal agents.
Topics: CD4-Positive T-Lymphocytes; HIV Infections; HIV-1; Humans; Ikaros Transcription Factor; Proviruses; | 2022 |
Neurological worsening during treatment of HIV-negative cryptococcal meningitis in a patient with Evans syndrome.
Topics: Adrenal Cortex Hormones; Antifungal Agents; Female; HIV Infections; Humans; Immune Reconstitution In | 2023 |
Population Pharmacokinetic Model to Assess the Impact of Disease State on Thalidomide Pharmacokinetics.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Fema | 2020 |
Two cases of immune reconstitution inflammatory syndrome in HIV patients treated with thalidomide.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Brain Edema; Do | 2019 |
Two cases of immune reconstitution inflammatory syndrome in HIV patients treated with thalidomide.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Brain Edema; Do | 2019 |
Two cases of immune reconstitution inflammatory syndrome in HIV patients treated with thalidomide.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Brain Edema; Do | 2019 |
Two cases of immune reconstitution inflammatory syndrome in HIV patients treated with thalidomide.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Brain Edema; Do | 2019 |
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2021 |
The management of Castleman disease.
Topics: Adrenal Cortex Hormones; Anti-Retroviral Agents; Antibodies, Monoclonal; Antineoplastic Combined Che | 2021 |
Apremilast for a psoriasis patient with HIV and hepatitis C.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Pso | 2017 |
Thalidomide as a Potential HIV Latency Reversal Agent: Is It the Right Time to Forget the Ancestral Sins?
Topics: CD4-Positive T-Lymphocytes; HIV Infections; HIV-1; Humans; Immunomodulation; Immunosuppressive Agent | 2017 |
CUL5 is required for thalidomide-dependent inhibition of cellular proliferation.
Topics: Biomarkers; Cell Nucleus; Cell Proliferation; Cells, Cultured; Cullin Proteins; Endothelial Cells; H | 2018 |
Apremilast as therapeutic option in a HIV positive patient with severe psoriasis.
Topics: Anti-HIV Agents; Anti-Inflammatory Agents, Non-Steroidal; HIV Infections; Humans; Male; Middle Aged; | 2018 |
Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Hepatitis B; HIV Infectio | 2019 |
Apremilast and phototherapy for treatment of psoriasis in a patient with human immunodeficiency virus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; HIV Infections; Humans; Male; Middle Aged; Phototherapy; Ps | 2019 |
A unique presentation of multiple myeloma in an HIV patient.
Topics: Aged; HIV; HIV Infections; HIV Seropositivity; Humans; Male; Multiple Myeloma; Radiography; Thalidom | 2013 |
Recalcitrant pseudotumoral anogenital herpes simplex virus type 2 in HIV-infected patients: evidence for predominant B-lymphoplasmocytic infiltration and immunomodulators as effective therapeutic strategy.
Topics: Acyclovir; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Herpes Genitalis; Herpesvi | 2013 |
Thalidomide in the treatment of immune reconstitution inflammatory syndrome in HIV patients with neurological tuberculosis.
Topics: AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active | 2014 |
Pseudotumoral recto-sigmoid herpes simplex virus type 2 in an HIV-infected patient: Dramatic improvement with thalidomide.
Topics: Adult; Female; Granuloma, Plasma Cell; Herpes Genitalis; Herpesvirus 2, Human; HIV Infections; Human | 2016 |
Human Immunodeficiency Virus Related Myelofibrosis Responsive to Low Dose Thalidomide.
Topics: Angiogenesis Inhibitors; HIV Infections; Humans; Primary Myelofibrosis; Thalidomide | 2016 |
[Clinical features and outcomes: analysis of 9 cases of HIV-negtive plasmablastic lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival | 2016 |
Complete regression of HIV-associated multicentric Castleman disease treated with rituximab and thalidomide.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Castleman Disease; HIV Infections; H | 2008 |
Images in HIV/AIDS. Stevens-Johnson syndrome associated with thalidomide treatment in HIV infection.
Topics: Adolescent; Anti-HIV Agents; HIV Infections; Humans; Male; Oral Ulcer; Stevens-Johnson Syndrome; Tha | 2008 |
Use of thalidomide in the management of three HIV seroreactive children with Kaposi's sarcoma referred for palliative care.
Topics: Adolescent; Angiogenesis Inhibitors; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studie | 2008 |
Treatment of 5q-syndrome with lenalidomide in an HIV-positive patient under cART.
Topics: Anti-HIV Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Therapy, Combination; HIV Inf | 2010 |
Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highl | 2010 |
Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs.
Topics: CD8-Positive T-Lymphocytes; Cells, Cultured; Dendritic Cells; Electroporation; gag Gene Products, Hu | 2012 |
Lenalidomide enhancement of human T cell functions in human immunodeficiency virus (HIV)-infected and HIV-negative CD4 T lymphocytopenic patients.
Topics: Adult; CD4-CD8 Ratio; Chemotaxis; HIV Infections; Humans; Interleukin-2; Lenalidomide; Male; Middle | 2012 |
Idiopathic ileocolitis with perforation associated with HIV infection: thalidomide treatment.
Topics: Adult; Crohn Disease; HIV Infections; Humans; Immunosuppressive Agents; Intestinal Perforation; Male | 2012 |
Transient increase in plasma HIV-1 viral load and associated weight gain after thalidomide dosing.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Thalidomide; Viral | 2002 |
Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro.
Topics: Adjuvants, Immunologic; CD8-Positive T-Lymphocytes; Cell Division; Coculture Techniques; Cytokines; | 2003 |
Successful treatment of a patient with HIV-associated multicentric Castleman disease (MCD) with thalidomide.
Topics: Adult; Angiogenesis Inhibitors; Castleman Disease; HIV Infections; Humans; Immunosuppressive Agents; | 2004 |
[Thalidomide in the treatment of recurrent plasmocitomas in an HIV-infected patient].
Topics: HIV Infections; Humans; Male; Middle Aged; Plasmacytoma; Recurrence; Thalidomide | 2004 |
Severe and unresponsive HIV-associated alopecia areata successfully treated with thalidomide.
Topics: Administration, Oral; Adult; Alopecia; Diagnosis, Differential; HIV Infections; Humans; Male; Severi | 2005 |
Erythema nodosum leprosum and HIV infection: A therapeutic experience.
Topics: Adult; Anti-HIV Agents; Colchicine; Erythema Nodosum; HIV Infections; Humans; Ibuprofen; Leprostatic | 2005 |
A retrospective analysis of thalidomide therapy in non-HIV-related Kaposi's sarcoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Female; HIV Infectio | 2007 |
Thalidomide treatment for refractory HIV-associated colitis: a case series.
Topics: Adult; Colitis; Colon; Colonoscopy; HIV Infections; Humans; Immunosuppressive Agents; Intestinal Muc | 2008 |
Thalidomide-resistant HIV-associated aphthae successfully treated with granulocyte colony-stimulating factor.
Topics: Adult; Granulocyte Colony-Stimulating Factor; HIV Infections; Humans; Stomatitis, Aphthous; Thalidom | 1995 |
Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide.
Topics: Acquired Immunodeficiency Syndrome; HIV Infections; Humans; Male; Middle Aged; Photosensitivity Diso | 1995 |
[Efficacy of thalidomide in the treatment of esophageal ulcers in human immunodeficiency virus infection].
Topics: Acquired Immunodeficiency Syndrome; Adult; Esophageal Diseases; Fatal Outcome; HIV Infections; HIV S | 1995 |
[Prolonged treatment with thalidomide in a patient with HIV infection].
Topics: Adult; HIV Infections; Humans; Male; Thalidomide; Time Factors | 1995 |
Thalidomide in oral aphthous ulceration in patients with HIV infection.
Topics: Adult; Female; HIV Infections; HIV-1; Humans; Male; Stomatitis, Aphthous; Thalidomide | 1994 |
Thalidomide for severe aphthous ulceration in patients with human immunodeficiency virus (HIV) infection.
Topics: Digestive System Diseases; HIV Infections; Humans; Severity of Illness Index; Stomatitis, Aphthous; | 1994 |
Autoimmunity in human immunodeficiency virus infection and the use of thalidomide.
Topics: Autoantibodies; HIV Infections; Humans; Thalidomide | 1994 |
[Efficacy of thalidomide against esophageal ulceration in HIV infection].
Topics: Adult; Esophageal and Gastric Varices; HIV Infections; Humans; Male; Stomatitis, Aphthous; Thalidomi | 1993 |
Thalidomide inhibits the replication of human immunodeficiency virus type 1.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cell Line; Female; HIV Infections; HIV-1; Humans; Leukocy | 1993 |
[Treatment with thalidomide and production of tumor necrosis factor alpha].
Topics: Graft vs Host Disease; HIV Infections; Humans; Thalidomide; Tumor Necrosis Factor-alpha | 1993 |
Thalidomide treatment of mucosal ulcerations in HIV infection.
Topics: Adolescent; Female; Fissure in Ano; HIV Infections; Humans; Immunosuppressive Agents; Stomatitis, Ap | 1996 |
Thalidomide treatment of mucosal ulcerations in HIV infection.
Topics: HIV Infections; Humans; Leprostatic Agents; Stomatitis, Aphthous; Thalidomide | 1996 |
Idiopathic esophageal ulceration associated with human immunodeficiency virus infection: efficacy of thalidomide treatment.
Topics: Adult; Anti-Ulcer Agents; Esophageal Diseases; HIV Infections; Humans; Male; Thalidomide; Ulcer | 1996 |
Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide.
Topics: Adolescent; DNA, Viral; Female; Granulocyte Colony-Stimulating Factor; Herpesvirus 8, Human; HIV Inf | 1996 |
Adverse reactions to thalidomide in patients infected with human immunodeficiency virus.
Topics: Adult; CD4 Lymphocyte Count; Female; Fever; HIV Infections; Humans; Male; Prospective Studies; Skin; | 1997 |
Thalidomide for aphthous ulcers in HIV infection.
Topics: HIV Infections; Humans; Stomatitis, Aphthous; Thalidomide; Viral Load | 1997 |
Thalidomide use is associated with weight gain in HIV-1-positive clients.
Topics: Adult; Female; HIV Infections; HIV Wasting Syndrome; HIV-1; Humans; Immunosuppressive Agents; Male; | 1997 |
Severe oral ulceration in patients with HIV infection: a case series.
Topics: Acquired Immunodeficiency Syndrome; Adult; Clinical Protocols; Decision Trees; Diagnosis, Differenti | 1997 |
Effects of thalidomide therapy in symptomatic simian immunodeficiency virus-infected cynomolgus monkeys.
Topics: Administration, Oral; Animals; CD28 Antigens; HIV Infections; Humans; Immunosuppressive Agents; Maca | 1998 |
Thalidomide pros and cons.
Topics: Double-Blind Method; Female; HIV Infections; HIV Wasting Syndrome; Humans; Immunosuppressive Agents; | 1998 |
Thwarting the dwindling progression of cachexia.
Topics: Cachexia; HIV Infections; Humans; Neoplasms; Thalidomide | 1998 |
Thalidomide's tightly controlled "comeback".
Topics: Autoimmune Diseases; HIV Infections; Humans; Immunosuppressive Agents; Leprostatic Agents; Thalidomi | 1999 |
The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro.
Topics: Anti-HIV Agents; Base Sequence; Cell Line; DNA Primers; Gene Expression; HIV Infections; HIV-1; Huma | 2000 |
Thalidomide's ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4+ cells in their blood.
Topics: Adjuvants, Immunologic; CD4-Positive T-Lymphocytes; HIV Infections; Humans; Interleukin-2; Thalidomi | 2000 |
Tumor necrosis factor-alpha increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection.
Topics: HIV Infections; Humans; Thalidomide; Tuberculosis, Pulmonary; Tumor Necrosis Factor-alpha | 2000 |
Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro.
Topics: Adjuvants, Immunologic; Adult; Apoptosis; Cyclic AMP; Dinoprostone; Drug Synergism; Female; HIV Infe | 2000 |
The re-emergence of thalidomide: results of a scientific conference.
Topics: Abnormalities, Drug-Induced; Adjuvants, Immunologic; Adolescent; Adult; Anti-HIV Agents; Anti-Inflam | 2000 |
Successful treatment of idiopathic colitis and proctitis using thalidomide in persons infected with human immunodeficiency virus.
Topics: Adult; Colitis, Ulcerative; HIV Infections; Humans; Immunosuppressive Agents; Male; Middle Aged; Pro | 1998 |
Thalidomide and HIV: several possible uses.
Topics: AIDS-Related Opportunistic Infections; Cachexia; Clinical Trials as Topic; HIV Infections; Humans; N | 1995 |
Or is it the host, sir?
Topics: Adjuvants, Immunologic; AIDS-Related Opportunistic Infections; Anti-Infective Agents; CD8-Positive T | 1996 |
Measurement of body composition: the search for a standard.
Topics: Adult; Biomarkers; Body Water; Extracellular Space; Female; HIV Infections; HIV Wasting Syndrome; Hu | 1997 |
Weight loss update.
Topics: AIDS-Related Opportunistic Infections; Appetite Stimulants; Female; Growth Hormone; HIV Infections; | 1996 |
NIH conference on AIDS wasting syndrome. National Institutes of Health.
Topics: Appetite; Body Composition; Child; Energy Metabolism; Exercise; HIV Infections; HIV Wasting Syndrome | 1997 |
Thalidomide shows benefit for microsporidial diarrhea.
Topics: Antiprotozoal Agents; Clinical Trials as Topic; Diarrhea; HIV Infections; Microsporidiosis; Thalidom | 1997 |
The rehabilitation of thalidomide.
Topics: Abnormalities, Drug-Induced; CD4 Lymphocyte Count; Conflict of Interest; Contraception; Drug Approva | 1998 |
Thalidomide's long and winding road.
Topics: Abnormalities, Drug-Induced; Clinical Trials as Topic; Drug Approval; Female; Health Services Access | 1998 |
The thalidomide comeback.
Topics: AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Clinical Trials as Topic; HIV Infection | 1998 |
Simply stated...are people still wasting?
Topics: AIDS-Related Opportunistic Infections; Appetite Stimulants; Energy Intake; Growth Hormone; HIV Infec | 1998 |
Use of thalidomide in HIV infection.
Topics: Adrenal Cortex Hormones; AIDS-Related Opportunistic Infections; HIV Infections; Humans; Recurrence; | 2001 |
Aphthous ulcers in HIV-infected patients: treatment with thalidomide.
Topics: Adult; HIV Infections; Humans; Male; Stomatitis, Aphthous; Thalidomide | 1992 |
HIV-associated oesophageal ulcers treated with thalidomide.
Topics: Esophageal Diseases; HIV Infections; Humans; Male; Middle Aged; Thalidomide; Ulcer | 1990 |
[Thalidomide, the treatment of choice in aphthae in HIV infection].
Topics: HIV Infections; Humans; Stomatitis, Aphthous; Thalidomide | 1990 |
Recurrent aphthous ulcer in patient infected with human immunodeficiency virus: successful treatment with thalidomide.
Topics: Administration, Topical; HIV Infections; Homosexuality; Humans; Male; Middle Aged; Mouth Mucosa; Rec | 1990 |
Thalidomide--a therapy for the immunological consequences of HIV infection?
Topics: Adjuvants, Immunologic; Autoimmune Diseases; B-Lymphocytes; HIV Infections; Humans; Lymphocyte Activ | 1989 |